Giamarellos-Bourboulis E J, Sambatakou H, Grecka P, Giamarellou H
1st Department of Propaedeutic Medicine, Athens Medical School, Laiko General Hospital, Greece.
Eur J Clin Microbiol Infect Dis. 1998 Sep;17(9):657-61. doi: 10.1007/BF01708351.
In a study designed to obtain data on compounds active against enterococci, the minimum inhibitory concentrations (MICs) of quinupristin/dalfopristin (RP 59500) and the novel quinolones DU-6859a, trovafloxacin, levofloxacin, and sparfloxacin were determined for 122 Enterococcus faecalis and seven Enterococcus faecium isolates. In addition, 15 Enterococcus faecalis isolates resistant to gentamicin, DU-6859a, and trovafloxacin were exposed over time to combinations of DU-6859a plus gentamicin and trovafloxacin plus gentamicin. DU-6859a and trovafloxacin were found to be the most active compounds against Enterococcus faecalis and DU-6859a and RP 59500 against Enterococcus faecium. Synergy between either DU-6859a or trovafloxacin and gentamicin was observed with 27 to 35% of the isolates. It is concluded that DU-6859a and trovafloxacin are very potent against enterococci, especially when combined with gentamicin.
在一项旨在获取抗肠球菌活性化合物数据的研究中，测定了122株粪肠球菌和7株屎肠球菌分离株对奎奴普丁/达福普汀（RP 59500）以及新型喹诺酮类药物DU - 6859a、曲伐沙星、左氧氟沙星和司帕沙星的最低抑菌浓度（MIC）。此外，使15株对庆大霉素、DU - 6859a和曲伐沙星耐药的粪肠球菌分离株长时间暴露于DU - 6859a加庆大霉素以及曲伐沙星加庆大霉素的联合用药中。发现DU - 6859a和曲伐沙星是对粪肠球菌活性最强的化合物，而DU - 6859a和RP 59500是对屎肠球菌活性最强的化合物。观察到27%至35%的分离株中DU - 6859a或曲伐沙星与庆大霉素之间存在协同作用。得出的结论是，DU - 6859a和曲伐沙星对肠球菌非常有效，尤其是与庆大霉素联合使用时。
